US Patent
US7863288 — Compounds and methods for kinase modulation, and indications therefor
Composition of Matter · Assigned to Plexxikon Inc · Expires 2029-06-20 · 3y remaining
Vulnerability score
15/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects compounds that modulate protein kinases and methods for using these compounds to treat diseases associated with aberrant protein kinase activity.
USPTO Abstract
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
Drugs covered by this patent
- Zelboraf (vemurafenib) · Hoffmann La Roche
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.